Bourgeon Capital Management LLC Acquires 500 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Bourgeon Capital Management LLC raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 1,000.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 550 shares of the company’s stock after purchasing an additional 500 shares during the period. Bourgeon Capital Management LLC’s holdings in CRISPR Therapeutics were worth $34,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Granite Bay Wealth Management LLC grew its holdings in shares of CRISPR Therapeutics by 25.2% in the 4th quarter. Granite Bay Wealth Management LLC now owns 20,433 shares of the company’s stock valued at $1,179,000 after buying an additional 4,116 shares during the period. Capital Advisors Inc. OK grew its stake in CRISPR Therapeutics by 10.1% in the fourth quarter. Capital Advisors Inc. OK now owns 255,265 shares of the company’s stock valued at $15,980,000 after acquiring an additional 23,340 shares during the period. Perigon Wealth Management LLC increased its holdings in shares of CRISPR Therapeutics by 4.3% in the fourth quarter. Perigon Wealth Management LLC now owns 14,918 shares of the company’s stock worth $934,000 after acquiring an additional 609 shares in the last quarter. Custom Index Systems LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $601,000. Finally, Krilogy Financial LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $982,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CRSP. Barclays lifted their price target on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Mizuho boosted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Morgan Stanley upped their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Finally, Wells Fargo & Company upped their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $74.93.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the sale, the chief executive officer now owns 187,377 shares in the company, valued at approximately $11,338,182.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares of the company’s stock, valued at approximately $11,338,182.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. In the last three months, insiders sold 114,410 shares of company stock worth $7,984,677. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $58.73 on Tuesday. The company has a fifty day moving average price of $73.89 and a two-hundred day moving average price of $63.30. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The stock has a market cap of $4.99 billion, a P/E ratio of -29.96 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. The company’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.41) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.